BIND Therapeutics (BIND) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update
May 9, 2016 7:00 AM EDTCompany does not anticipate disruption in operations under Chapter 11 protection
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today reported financial results for the first quarter ended March 31, 2016 and provided a business update.
"Despite our financial challenges, we remain committed to advancing our new R&D strategy of applying our ACCURINS® technology to develop innovative medicines and we have made significant progress during the first quarter, said Andrew Hirsch, president and chief executive officer at BIND... More
